Microsoft word - lipibor_eng.doc
Lipibor is a proprietary blend of natural ingredients, scientifically
developed to lower blood cholesterol. It contains high quality
standardized extracts of Policosanol, Beta-glucan and Niacin. Each
ingredient plays an integral role in cholesterol management and
together having complimentary and synergistic effects.
Actions and Pharmacology
works by blocking the body’s synthesis of cholesterol. It
reduces total cholesterol, LDL (bad cholesterol), and increases HDL
(good cholesterol). It also appears to inhibit the oxidation of LDL.
Oxidized LDL creates a chronic inflammatory response that promotes
destruction of blood vessels. Policosanol has a direct effect on the liver
cells and cholesterol metabolism. It helps binding LDL to receptors,
transporting LDL to the liver and facilitating its break down. It inhibits
excessive platelet aggregation. However, its effects on triglyceride are
has been proven to improve the lipoprotein profile. It is
effective at reducing total cholesterol, LDL, and triglyceride levels,
while at the same time raising HDL levels. It lowers cholesterol and
triglyceride by blocking their excess production by liver. It has
synergistic effect with statins in lowering cholesterol. Niacin inhibits
lipoprotein lipids, decreases fatty acid transfer to the liver, decreases
hepatic triglyceride synthesis and VLDL synthesis, and facilitates the
excretion. Niacin stimulates HDL synthesis.
Clinical trial shows that Niacin decreases VLDL and triglyceride by 35%
to 40% within days, increases HDL by 10% to 14%, and decreases
LDL by 20% to 30% within weeks. Beta glucan
has been found to lower total cholesterol levels as well as
to increase levels of HDL-cholesterol. The mechanism of the HDL-
elevation activity is unknown. Also, it is not well understood how beta
glucan lowers total cholesterol levels. It is thought that the
cholesterol-lowering effect of beta glucan may be accounted for, in
large part by, its promotion of the excretion of bile acids.
Beta glucan appears to be a non-specific immune enhancer via its
ability, among other possible mechanisms, to activate macrophages. It
may have some anti-carcinogenic, anti-atherosclerotic and anti-
inflammatory effects. It may enhance wounds healing and promote skin health in some circumstances. Combination Lipibor
The three ingredients of Lipibor have synergistic and complementary effect in relation to lowering total cholesterol, LDL, VLDL, and triglycerides while at the same time increasing HDL. In addition, Lipibor is a platelet anti-aggregant and immunomodulator.
Complementary effect of triple combination (Lipibor)
Mechanism of Action of Lipibor on cholesterol metabolism
Indications and Usage
Lipibor is indicated as a supportive measure to dietary and lifestyle
recommendations to reduce elevated cholesterol levels.
Lipibor lowers LDL (bad) cholesterol and increases HDL (good) cholesterol and helps prevent atherosclerosis. It may reduce platelet aggregation in both healthy and hypercholesterolemic individuals, which may be of beneficial to individuals with intermittent claudication.
The recommended starting dose is 1 capsule daily at dinner time or
right before going to bed, since cholesterol synthesis is increased at
Lipibor produces beneficial effects on cholesterol control within the first
6-8 weeks of use. An effect may take up to 12 weeks to be observed.
The dose can be doubled to 1 capsule twice a day, taken at lunch and
The American Heart Association (AHA) recommends that total
cholesterol level not to exceed 5.17 mmol. Therefore, we recommend
in low risk patients to start taking Lipibor if the cholesterol level is
above this level. If the cholesterol level is between 5.17 to 6.20
mmol/l then 1 capsule of Lipibor per day is recommended; if the
cholesterol level is higher than 6.20 mmol/l then 2 capsules per day
should be taken.
How to achieve the best results with Lipibor
To maximize your cholesterol control it is essential to combine the
following three elements:
Clinical trial shows that Policosanol is at least as effective as Lovastatin
in lowering cholesterol. Policosanol lowers total cholesterol by 17.5%,
LDL by 31%, and increases HDL by 31.5%. It significantly reduced
fibrinogen level. On the other hand, Lovastatin decreased total
cholesterol by 18% and LDL by 22.6%.
Angiology 2003, Jan; 54(1): 25-38.
In addition, this trial showed that Policosanol is a suitable alternative
to manage patients with intermittent claudication because of multiple
properties beyond its cholesterol lowering effects.
Castamo G et al. Drugs Exp. Clin. Res. 2005: 31 Supp. 31-44
Niacin is more effective than Lopid (gemfirozil). Am.J Cardiol. 2000 Dec 21; 86(12A): 461-501 In a direct comparison study, niacin increased HDL more than gemfibrozil [Lopid], and decreased the total cholesterol-to-HDL ratio, lipoprotein (a) (Lp[a]), and fibrinogen levels significantly more.
Interactions and Synergism
Lipibor has synergistic effect with other cholesterol lowering agents
Lipibor showed a synergism with the anti-thrombotic properties of
aspirin in different experimental models.
Lipibor has no side effects (completely safe). It has no adverse drug
interaction, can be used in diabetes, elderly subjects and patients with
impaired liver function.
Pregnancy and Breastfeeding
Use of Lipibor supplementation during pregnancy or breastfeeding is
not recommended due to a lack of sufficient research of safety and
Easy once a day dosing at bedtime As effective as pharmaceuticals It is safe Low cost
is a trade-mark of BOROLA. The product has been
manufactured in the USA in compliance with the highest standards of
Good Manufacturing Practice (GMP). Lipibor is a food supplement.
Store at a temperature below 30º С, do not leave reach of children.
For consultations with a medical specialist, please, refer to
Clinic Borola, 52 Tzar Simeon Street, Sofia 1202, Bulgaria.
Phone: +359 2 9156 102; e-mail: firstname.lastname@example.org
THE ENERGY IN ALBANIA (NEWSLETTER) Other issues are available on EEC website PUBLISHED BY THE “ALBANIA-EU ENERGY EFFICIENCY ALBANIA CENTRE” (EEC) ISSUE NO 45 • DECEMBER 2008 REGIONAL ENERGY DEMAND PLANNING PROJECT Inside this Issue 3. Development of the National Energy - REGIONAL ENERGY DEMAND PLANNING Planning Models - ESTABLISHMENT OF THE
LES SCÉNARIOS VIDÉO SCÉNARIO 1 : « À l’Urgence » Partie 1 – Version 1 de l’entrevue CADRE Une salle d’examen, à l’Urgence. PROTAGONISTES Patient : homme au début de la quarantaine, légèrement trop gras, portant des shorts. Il affiche un comportement impatient qui va en empirant car ses attentes ne sont pas satisfaites par le médecin. DHCEU : agréable,